This article is more than 5 years old. Information may no longer be current.

Pegaptanib moderately reduces foveal thickness in eyes with AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Administering intravitreal injections of pegaptanib at 6-week intervals can lead to a moderate reduction in central foveal thickness in eyes with subfoveal neovascular age-related macular degeneration, a study found.

Geoffrey G. Emerson, MD, PhD, and colleagues used optical coherence tomography to measure macular thickness in 41 eyes of 41 patients during intravitreous 1 mg injections of Macugen (pegaptanib sodium, Pfizer), which were administered every 6 weeks, according to the study.

At 12 weeks follow-up, mean central foveal thickness decreased from 340 µm to 299 µm, a reduction of 32%, the authors reported.

Additionally, fluorescein angiograms with definite leakage decreased from 100% to 81%, while mean visual acuity decreased from 20/116 to 20/120, they found.

"[Pegaptanib produces] a modest effect relative to that reported with other anti-angiogenic agents," the authors said.

The study is published in the July/August issue of Retina.